{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:05:48Z","timestamp":1792724748125,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jbo.2021.100355","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T03:22:32Z","timestamp":1616124152000},"page":"100355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-9097","authenticated-orcid":false,"given":"Komal","family":"Waqas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Lima Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10071","key":"10.1016\/j.jbo.2021.100355_b0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","article-title":"The global burden of women's cancers: a grand challenge in global health","volume":"389","author":"Ginsburg","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2021.100355_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.07.002","article-title":"Breast Cancer Epidemiology, Prevention, and Screening","volume":"151","author":"Winters","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0360-3016(92)90895-O","article-title":"Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer","volume":"23","author":"Pierce","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0020","doi-asserted-by":"crossref","DOI":"10.1002\/j.2617-1619.2019.tb00011.x","article-title":"Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia","volume":"2","author":"Hain","year":"2019","journal-title":"JCSM Rapid Commun."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/ejso.2002.1337","article-title":"The effect of chemotherapy on the morphology of the growth plate and metaphysis of the growing skeleton","volume":"29","author":"van Leeuwen","year":"2003","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100254","article-title":"Incidence of fractures in young women with breast cancer - a retrospective cohort study","volume":"18","author":"Stumpf","year":"2019","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0035","unstructured":"Rao RD, Cobleigh MA. Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012;26(6):541-7, 50, 52 passim."},{"key":"10.1016\/j.jbo.2021.100355_b0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-70197-4_2","article-title":"Adjuvant Endocrine Therapy","volume":"173","author":"Shah","year":"2018","journal-title":"Cancer Treat. Res."},{"issue":"11","key":"10.1016\/j.jbo.2021.100355_b0045","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00198-018-4642-2","article-title":"The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer","volume":"29","author":"Kyvernitakis","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2021.100355_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100254","article-title":"Incidence of fractures in young women with breast cancer - a retrospective cohort study","volume":"18","author":"Stumpf","year":"2019","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol."},{"issue":"9","key":"10.1016\/j.jbo.2021.100355_b0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.jbo.2021.100355_b0065","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisd\u00f3ttir","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2021.100355_b0075","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","article-title":"Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy","volume":"26","author":"Kalder","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2021.100355_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-019-01063-0","article-title":"Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors","author":"Catalano","year":"2019","journal-title":"J. Endocrinol. Invest."},{"issue":"7","key":"10.1016\/j.jbo.2021.100355_b0090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"New Engl J Med."},{"key":"10.1016\/j.jbo.2021.100355_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","author":"Perrone","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.jbo.2021.100355_b0105","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00198-018-4642-2","article-title":"The tamoxifen paradox\u2014influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer","volume":"29","author":"Kyvernitakis","year":"2018","journal-title":"Osteoporosis Int."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","article-title":"Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women","volume":"17","author":"Heshmati","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol."},{"issue":"5\u20136","key":"10.1016\/j.jbo.2021.100355_b0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000323489","article-title":"Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy","volume":"79","author":"Aihara","year":"2010","journal-title":"Oncology."},{"issue":"3","key":"10.1016\/j.jbo.2021.100355_b0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.breast.2009.03.003","article-title":"The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial","volume":"18","author":"Hadji","year":"2009","journal-title":"Breast."},{"issue":"4","key":"10.1016\/j.jbo.2021.100355_b0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","article-title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","volume":"22","author":"Eastell","year":"2011","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0135","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/annonc\/mdr448","article-title":"Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1\u201398 study (SAKK 21\/07)","volume":"23","author":"Zaman","year":"2012","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-2849-2","article-title":"Bone mineral density and circulating biomarkers in the BIG 1\u201398 trial comparing adjuvant letrozole, tamoxifen and their sequences","volume":"144","author":"Decensi","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"9484","key":"10.1016\/j.jbo.2021.100355_b0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jbo.2021.100355_b0150","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.jbo.2021.100355_b0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J. Natl Cancer Inst."},{"issue":"4","key":"10.1016\/j.jbo.2021.100355_b0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1759720X18759291","article-title":"Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis","volume":"10","author":"Tseng","year":"2018","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"10.1016\/j.jbo.2021.100355_b0165","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05289-7","article-title":"Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study","author":"Pineda-Moncus\u00ed","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11864-018-0541-1","article-title":"Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer","volume":"19","author":"van Hellemond","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0175","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ijc.32205","article-title":"Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study","volume":"145","author":"van Hellemond","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100355_b0180","doi-asserted-by":"crossref","unstructured":"Van Hellemond IE, Smorenburg CH, Peer PG, Swinkels AC, Seynaeve CM, Van Der Sangen MJ, et al. No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: a sub-study of the DATA trial. Cancer research. 2019;79(4).","DOI":"10.1158\/1538-7445.SABCS18-P4-14-11"},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: A systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J. Natl Cancer Inst."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0195","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11764-017-0622-3","article-title":"Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses","volume":"11","author":"Fornusek","year":"2017","journal-title":"J. Cancer Surviv."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0200","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00198-011-1761-4","article-title":"Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial","volume":"23","author":"Saarto","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/oby.21729","article-title":"The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors","volume":"25","author":"Thomas","year":"2017","journal-title":"Obesity."},{"key":"10.1016\/j.jbo.2021.100355_b0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.exger.2018.07.022","article-title":"Effects of resistance plus aerobic training on body composition and metabolic markers in older breast cancer survivors undergoing aromatase inhibitor therapy","volume":"111","author":"de Paulo","year":"2018","journal-title":"Exp. Gerontol."},{"issue":"8","key":"10.1016\/j.jbo.2021.100355_b0215","first-page":"2675","article-title":"The effects of high-dose calcitriol and individualized exercise on bone metabolism in breast cancer survivors on hormonal therapy: a phase II feasibility trial","volume":"26","author":"Peppone","year":"2018","journal-title":"Supportive Care Cancer."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-015-3541-x","article-title":"Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial","volume":"153","author":"Casla","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"30","key":"10.1016\/j.jbo.2021.100355_b0225","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2012.42.0638","article-title":"Lifestyle factors in cancer survivorship","volume":"30","author":"Ligibel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2021.100355_b0230","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2131\/jts.37.617","article-title":"Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1\u201334))","volume":"37","author":"Watanabe","year":"2012","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.jbo.2021.100355_b0235","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","author":"Jolette","year":"2017","journal-title":"Regul. Toxicol. Pharm."},{"issue":"8","key":"10.1016\/j.jbo.2021.100355_b0240","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/annonc\/mdr600","article-title":"Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study","volume":"23","author":"Nuzzo","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0245","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","article-title":"Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial","volume":"114","author":"Kyvernitakis","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2021.100355_b0250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2021.100355_b0255","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer."},{"issue":"11","key":"10.1016\/j.jbo.2021.100355_b0265","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0270","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2 Suppl 7","key":"10.1016\/j.jbo.2021.100355_b0275","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","article-title":"Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update","volume":"33","author":"Brufsky","year":"2006","journal-title":"Semin. Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1758834011420599","article-title":"Zoledronic acid in breast cancer: latest findings and interpretations","volume":"3","author":"Gnant","year":"2011","journal-title":"Ther Adv Med Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0285","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0290","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","article-title":"Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial","volume":"26","author":"Greenspan","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"19","key":"10.1016\/j.jbo.2021.100355_b0295","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.jbo.2021.100355_b0300","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","article-title":"Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial","volume":"15","author":"Sestak","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1507\/endocrj.EJ12-0283","article-title":"Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(R)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study","volume":"60","author":"Rhee","year":"2013","journal-title":"Endocr. J."},{"key":"10.1016\/j.jbo.2021.100355_b0310","article-title":"Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates","author":"Pineda-Moncus\u00ed","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer."},{"issue":"4","key":"10.1016\/j.jbo.2021.100355_b0320","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0325","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00774-018-0917-0","article-title":"Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer","volume":"37","author":"Nakatsukasa","year":"2019","journal-title":"J. Bone Miner. Metab."},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0330","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00774-017-0884-x","article-title":"Effect of denosumab administration on low bone mineral density (T-score \u22121.0 to \u22122.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer","volume":"36","author":"Nakatsukasa","year":"2018","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0335","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12282-018-0896-y","article-title":"Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results","volume":"26","author":"Nakatsukasa","year":"2019","journal-title":"Breast Cancer."},{"issue":"9992","key":"10.1016\/j.jbo.2021.100355_b0340","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0345","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"10001","key":"10.1016\/j.jbo.2021.100355_b0350","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jbo.2021.100355_b0355","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0360","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative G. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015, 386(10001):1353-61.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"10.1016\/j.jbo.2021.100355_b0365","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33035","article-title":"Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab","author":"Suarez-Almazor","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100355_b0370","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","author":"Gralow","year":"2019","journal-title":"J. Natl Cancer Inst."},{"issue":"7","key":"10.1016\/j.jbo.2021.100355_b0375","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-16-0547","article-title":"Oral Bisphosphonates and Improved Survival of Breast Cancer","volume":"23","author":"Rennert","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2021.100355_b0380","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2018.06.028","article-title":"Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors","volume":"101","author":"Bouvard","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2021.100355_b0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0390","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(19)30228-1","article-title":"Denosumab in early-stage breast cancer \u2013 Authors' reply","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0395","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","author":"Coleman","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2021.100355_b0400","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cen.13735","volume":"89","author":"Grossmann","year":"2018","journal-title":"Clin. Endocrinol."},{"issue":"11","key":"10.1016\/j.jbo.2021.100355_b0405","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer","volume":"6","author":"Rachner","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0410","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00198-018-4758-4","article-title":"Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations","volume":"30","author":"Hamood","year":"2019","journal-title":"Osteoporosis Int."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0415","first-page":"197","article-title":"Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience","volume":"26","author":"Tremblay","year":"2018","journal-title":"Supportive Care Cancer."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0420","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/GME.0000000000000515","article-title":"Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer","volume":"23","author":"Villa","year":"2016","journal-title":"Menopause."},{"issue":"5","key":"10.1016\/j.jbo.2021.100355_b0425","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0430","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","article-title":"Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study","volume":"97","author":"Pedersini","year":"2017","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.jbo.2021.100355_b0435","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00198-016-3899-6","article-title":"Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer","volume":"28","author":"Hong","year":"2017","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.jbo.2021.100355_b0440","unstructured":"Rodriguez-Sanz M, Pineda-Moncusi M, Garcia-Giralt N, Servitja S, Martos T, Blanch-Rubio J, et al. TBS variation in breast cancer women completing AI-therapy: a prospective study of the B-able cohort. Journal of bone and mineral research Conference: 2016 annual meeting of the american society for bone and mineral research, ASBMR 2016 United states. 2017;31(Supplement 1) (no pagination)."},{"key":"10.1016\/j.jbo.2021.100355_b0445","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbo.2016.10.004","article-title":"Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score","volume":"7","author":"Mariotti","year":"2017","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.jbo.2021.100355_b0450","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4636028","article-title":"FRAX Calculated without BMD Resulting in a Higher Fracture Risk Than That Calculated with BMD in Women with Early Breast Cancer","volume":"2018","author":"Prawiradilaga","year":"2018","journal-title":"J Osteoporosis."},{"key":"10.1016\/j.jbo.2021.100355_b0455","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3726","article-title":"Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study","author":"Leslie","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.jbo.2021.100355_b0460","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa306","article-title":"Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF","volume":"105","author":"Pepe","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.jbo.2021.100355_b0465","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-020-05640-3","article-title":"Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis","volume":"181","author":"Miyashita","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2021.100355_b0470","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","author":"Gonzalez-Rodriguez","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2021.100355_b0475","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.jbo.2021.100355_b0480","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00223-015-0040-3","article-title":"Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study","volume":"97","author":"Carbonell-Abella","year":"2015","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0485","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2021.100355_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2019.12.001","article-title":"Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy","author":"Hopson","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jbo.2021.100355_b0495","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2018.12.005","article-title":"Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial","volume":"108","author":"Livi","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100355_b0500","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","article-title":"Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04)","volume":"13","author":"Coleman","year":"2018","journal-title":"J Bone Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2021.100355_b0505","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-018-4811-1","article-title":"A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial","volume":"171","author":"Santa-Maria","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2021.100355_b0510","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bone.2019.04.016","article-title":"Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia","volume":"124","author":"Sestak","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2021.100355_b0515","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00632","article-title":"Improvement of bone physiology and life quality due to association of risedronate and anastrozole","volume":"8","author":"Monda","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:14Z","timestamp":1761941894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137421000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":103,"alternative-id":["S2212137421000099"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100355","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100355"}}